Production (Stage)
Aligos Therapeutics, Inc.
ALGS
$5.50
-$0.17-3.00%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 311.00K | 629.00K | 1.27M | 1.06M | 986.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 311.00K | 629.00K | 1.27M | 1.06M | 986.00K |
| Cost of Revenue | 14.50M | 16.03M | 16.77M | 21.10M | 16.37M |
| Gross Profit | -14.19M | -15.40M | -15.51M | -20.04M | -15.38M |
| SG&A Expenses | 5.05M | 5.16M | 4.63M | 6.38M | 6.67M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.55M | 21.19M | 21.40M | 27.48M | 23.03M |
| Operating Income | -19.24M | -20.56M | -20.13M | -26.41M | -22.05M |
| Income Before Tax | 43.13M | -82.12M | -19.17M | 5.25M | -34.84M |
| Income Tax Expenses | 43.00K | 27.00K | 91.00K | 189.00K | 24.00K |
| Earnings from Continuing Operations | 43.09M | -82.15M | -19.26M | 5.06M | -34.86M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 43.09M | -82.15M | -19.26M | 5.06M | -34.86M |
| EBIT | -19.24M | -20.56M | -20.13M | -26.41M | -22.05M |
| EBITDA | -19.05M | -20.32M | -19.88M | -26.16M | -21.76M |
| EPS Basic | 5.12 | -13.08 | -3.07 | 0.81 | -5.58 |
| Normalized Basic EPS | 3.21 | -8.17 | -1.91 | 0.52 | -3.49 |
| EPS Diluted | -2.11 | -13.08 | -3.07 | 0.75 | -5.58 |
| Normalized Diluted EPS | 3.10 | -8.17 | -1.91 | 0.52 | -3.49 |
| Average Basic Shares Outstanding | 8.41M | 6.28M | 6.27M | 6.26M | 6.25M |
| Average Diluted Shares Outstanding | 8.71M | 6.28M | 6.27M | 6.27M | 6.25M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |